Regeneron Pharmaceuticals Company Profile (NASDAQ:REGN)

Regeneron Pharmaceuticals trades on the NASDAQ under the ticker symbol "REGN."

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) posted its quarterly earnings results on Thursday, May, 4th. The company reported $2.92 EPS for the quarter, beating the consensus estimate of $2.50 by $0.42. The firm earned $1.32 billion during the quarter, compared to analysts' expectations of $1.30 billion. Regeneron Pharmaceuticals had a return on equity of 22.99% and a net margin of 19.34%. The company's revenue for the quarter was up 9.8% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.57 EPS. View Regeneron Pharmaceuticals' Earnings History.

Regeneron Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, August, 2nd 2017. View Earnings Estimates for Regeneron Pharmaceuticals.

25 analysts have issued twelve-month price targets for Regeneron Pharmaceuticals' shares. Their predictions range from $345.00 to $598.00. On average, they anticipate Regeneron Pharmaceuticals' stock price to reach $454.95 in the next year. View Analyst Ratings for Regeneron Pharmaceuticals.

Here are some recent quotes from research analysts about Regeneron Pharmaceuticals stock:

• 1. Cowen and Company analysts commented, "REGN reported Q1:17 U.S." (5/5/2017)
• 2. According to Zacks Investment Research, "Regeneron’s key growth driver, Eylea, continues to drive revenues at the company and the company is expanding the drug's label for additional indications. Regeneron received a major boost when Praluent became the first PCSK9 inhibitor to be approved (Jul 2015) in the U.S and the EU (Sep 2015). Although sales of Praluent have failed to impress due to the present payer utilization management restrictions in the U.S. and limited market access in Europe, the drug is still expected to have blockbuster potential. The FDA recently approved the companies' new supplemental Biologics License Application (sBLA) for a once-monthly, 300 mg dose of Praluent(alirocumab) Injection for the treatment of adults with high low-density. Investors should focus on pipeline catalysts - dupilumab and sarilumab. Shares of the company have also outperformed the industry in the last three months. Estimates have been stable in the last thirty days." (4/27/2017)
• 3. BMO Capital Markets analysts commented, "We raise our price target to $412 but maintain our Market Perform rating on REGN following Dupixent approval in adult atopic dermatitis. While the approval was widely expected and reflects the strength of Dupixent's clinical profile, we believe the $37k gross price (~$30k net) is higher than expected (BMO: ~$25k prior) and could lead to even more aggressive management by payors. Thus, while we have updated our model to reflect Dupixent's actual price, we have slowed our ramp on our expectation for increased access restrictions given the therapy's high price." (3/28/2017)
• 4. Robert W. Baird analysts commented, "We surveyed 30 dermatologists treating ~134 moderate-to-severe AD patients each on their expectations around the launches for Pfizer's Eucrisa and Regeneron/Sanofi's Dupixent, set for approval tomorrow. Docs highlighted the significant need for new mechanisms and therapeutic alternatives. Importantly, physician sentiment points to a market for Dupixent of about 300,000-350,000 patients, in line with management's expectations. We wouldn't be surprised to see an exceptionally strong launch here, but we continue to point out that consensus expectations are already building that in." (3/28/2017)

Some companies that are related to Regeneron Pharmaceuticals include Celgene Corporation (CELG), Gilead Sciences (GILD), Vertex Pharmaceuticals Incorporated (VRTX), TESARO (TSRO), Exelixis (EXEL), Bioverativ (BIVV), Kite Pharma (KITE), bluebird bio (BLUE), Clovis Oncology (CLVS), Neurocrine Biosciences (NBIX), Juno Therapeutics (JUNO), Intercept Pharmaceuticals (ICPT), China Biologic Products (CBPO), Ultragenyx Pharmaceutical (RARE), Axovant Sciences (AXON), Agios Pharmaceuticals (AGIO), GW Pharmaceuticals PLC (GWPH) and AveXis (AVXS).

Regeneron Pharmaceuticals' management team includes the folowing people:

• P. Roy Vagelos M.D., Chairman of the Board
• Leonard S. Schleifer M.D., Ph.D., President, Chief Executive Officer, Director
• Robert E. Landry, Chief Financial Officer, Senior Vice President - Finance
• Daniel P. Van Plew, Executive Vice President, General Manager - Industrial Operations and Product Supply
• Neil Stahl Ph.D., Executive Vice President - Research and Development
• Robert J. Terifay, Executive Vice President - Commercial
• Joseph J. LaRosa, Senior Vice President, General Counsel, Secretary
• Michael Aberman M.D., Senior Vice President - Strategy and Investor Relation
• Peter Powchik M.D., Senior Vice President - Clinical Development
• George D. Yancopoulos M.D., Ph.D., President and Chief Scientific Officer - Regeneron, Director

Regeneron Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include FMR LLC (6.28%), BlackRock Inc. (5.83%), Wellington Management Group LLP (5.82%), Vanguard Group Inc. (4.86%), State Street Corp (3.20%) and Artisan Partners Limited Partnership (1.83%). Company insiders that own Regeneron Pharmaceuticals stock include Arthur F Ryan, Charles A Baker, Douglas S Mccorkle, George Yancopoulos, Joseph L Goldstein, Michael S Aberman, Michael S Brown, Neil Stahl, P Roy Vagelos, Peter Powchik, Plew Daniel P Van, Robert J Terifay and Sanofi. View Institutional Ownership Trends for Regeneron Pharmaceuticals.

Regeneron Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Wells Fargo & Company MN, Winslow Capital Management LLC, Ameriprise Financial Inc., Manning & Napier Advisors LLC, Morgan Stanley, UBS Asset Management Americas Inc. and APG Asset Management N.V.. Company insiders that have sold Regeneron Pharmaceuticals stock in the last year include Arthur F Ryan, Charles A Baker, Joseph L Goldstein, Michael S Aberman, Michael S Brown, Neil Stahl, P Roy Vagelos and Robert J Terifay. View Insider Buying and Selling for Regeneron Pharmaceuticals.

Regeneron Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Janus Capital Management LLC, Wellington Management Group LLP, Clearbridge Investments LLC, Harding Loevner LP, Bank of New York Mellon Corp, Vanguard Group Inc. and American Century Companies Inc.. View Insider Buying and Selling for Regeneron Pharmaceuticals.

Shares of Regeneron Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Regeneron Pharmaceuticals stock can currently be purchased for approximately $513.19.